Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2016

Open Access 01-12-2016 | Research article

The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis

Authors: Karin Jakobsson, Lennart Jacobsson, Aladdin J. Mohammad, Jan-Åke Nilsson, Kenneth Warrington, Eric L. Matteson, Carl Turesson

Published in: BMC Musculoskeletal Disorders | Issue 1/2016

Login to get access

Abstract

Background

To investigate the effect of baseline clinical characteristics and glucocorticoid treatment on temporal artery biopsy (TAB) findings in patients with giant cell arteritis (GCA).

Methods

Individuals who developed GCA after inclusion in two population-based health surveys were identified through linkage to the local and the national patient registers. In addition, other patients diagnosed with GCA at the Departments of Internal Medicine and Rheumatology at an area hospital were included. A structured review of medical records and TAB pathology reports was performed. The presence or absence of giant cells, granuloma, fragmented internal elastic lamina, fibrosis and grade of inflammatory infiltrates were recorded.

Results

In 183 cases with a confirmed clinical diagnosis of GCA, 139 were biopsied after start of glucocorticoids (median treatment duration 3 days; interquartile range 2–5). Patients with a positive TAB (77 %) had significantly higher C-reactive protein (CRP; p = 0.007) and erythrocyte sedimentation rate (ESR; p = 0.03) at the time of clinical diagnosis. A positive TAB tended to more common in women, but there was no difference in the proportion of patients with polymyalgia rheumatica or visual symptoms.
Patients biopsied before or on the same day as initial treatment where more likely than those biopsied 1–3 days after treatment start to have positive biopsy [odds ratio (OR) 2.86; 95 % CI 1.06–7.70] as well as inflammatory infiltrates (OR 3.30; 95 % CI 1.15–9.49).
There was no significant difference in the proportions of a fragmented internal lamina (p = 0.86), giant cells (p = 0.10), granuloma (p = 0.19), minor inflammatory infiltrates (p = 0.47), major inflammatory infiltrates (p = 0.09), or overall positive biopsy (p = 0.17) report by treatment duration comparing: ≤ 0 days, 1–3 days, 4–6 days, 7–28 days. Among those biopsied 7–28 days after start of treatment, 80 % of TABs were positive, and histopathology features were not substantially different from those biopsied after shorter glucocorticoid treatment.

Conclusion

Biopsies were more likely to be positive and have characteristic histopathologic features in patients with high CRP and ESR, and prior to start of corticosteroid treatment TABs taken 1–4 weeks after initiation of glucocorticoid treatment reveal changes consistent with GCA and therefore still yields clinically useful information for the diagnosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Walvick MD, Walvick MP. Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy. Ophthalmology. 2011;118(6):1201–4.CrossRefPubMed Walvick MD, Walvick MP. Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy. Ophthalmology. 2011;118(6):1201–4.CrossRefPubMed
2.
go back to reference Mari B, Monteagudo M, Bustamante E, Perez J, Casanovas A, Jordana R, et al. Analysis of temporal artery biopsies in an 18-year period at a community hospital. Eur J Intern Med. 2009;20(5):533–6.CrossRefPubMed Mari B, Monteagudo M, Bustamante E, Perez J, Casanovas A, Jordana R, et al. Analysis of temporal artery biopsies in an 18-year period at a community hospital. Eur J Intern Med. 2009;20(5):533–6.CrossRefPubMed
3.
go back to reference Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C. Rodriguez-Ledo: Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum. 2001;30(4):249–56.CrossRefPubMed Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C. Rodriguez-Ledo: Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum. 2001;30(4):249–56.CrossRefPubMed
4.
go back to reference Narvaez J, Bernad B, Roig-Vilaseca D, Garcia-Gomez C, Gomez-Vaquero C, Juanola X, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum. 2007;37(1):13–9.CrossRefPubMed Narvaez J, Bernad B, Roig-Vilaseca D, Garcia-Gomez C, Gomez-Vaquero C, Juanola X, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum. 2007;37(1):13–9.CrossRefPubMed
5.
go back to reference Lugo JZ, Deitch JS, Yu A, Jang JH, Patel R, Slova D, et al. Demographic and laboratory data may predict positive temporal artery biopsy. J Surg Res. 2011;170(2):332–5.CrossRefPubMed Lugo JZ, Deitch JS, Yu A, Jang JH, Patel R, Slova D, et al. Demographic and laboratory data may predict positive temporal artery biopsy. J Surg Res. 2011;170(2):332–5.CrossRefPubMed
6.
go back to reference Chmelewski WL, McKnight KM, Agudelo CA, Wise CM. Presenting features and outcomes in patients undergoing temporal artery biopsy. A review of 98 patients. Arch Intern Med. 1992;152(8):1690–5.CrossRefPubMed Chmelewski WL, McKnight KM, Agudelo CA, Wise CM. Presenting features and outcomes in patients undergoing temporal artery biopsy. A review of 98 patients. Arch Intern Med. 1992;152(8):1690–5.CrossRefPubMed
7.
go back to reference Breuer GS, Nesher R, Reinus K, Nesher G. Association between histological features in temporal artery biopsies and clinical features of patients with giant cell arteritis. Isr Med Assoc J. 2013;15(6):271–4.PubMed Breuer GS, Nesher R, Reinus K, Nesher G. Association between histological features in temporal artery biopsies and clinical features of patients with giant cell arteritis. Isr Med Assoc J. 2013;15(6):271–4.PubMed
9.
go back to reference Achkar AA, Lie JT, Hunder GG, O’Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994;120(12):987–92.CrossRefPubMed Achkar AA, Lie JT, Hunder GG, O’Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994;120(12):987–92.CrossRefPubMed
10.
go back to reference Serafim AS, Piper J, Hutchings A, Bradburn M, Ponte C, et al. Early Halo Sign Features on Ultrasound Examination of Treated Patients with Giant Cell Arteritis. Nephron. 2015;129 Suppl 2:123–4. Serafim AS, Piper J, Hutchings A, Bradburn M, Ponte C, et al. Early Halo Sign Features on Ultrasound Examination of Treated Patients with Giant Cell Arteritis. Nephron. 2015;129 Suppl 2:123–4.
11.
go back to reference Singh S, Hutchings A, Forrester-Barker W, Dasgupta B, Diamantopoulos A, Lanyon P, et al. Preliminary Analysis of Histological Findings in GCA Biopsy Positive Patients Recruited into a Large Multicentre Study of Temporal Artery Ultrasound vs Biopsy in the Diagnosis of Giant Cell Arteritis (TABUL). Nephron. 2015;129 Suppl 2:84–5. Singh S, Hutchings A, Forrester-Barker W, Dasgupta B, Diamantopoulos A, Lanyon P, et al. Preliminary Analysis of Histological Findings in GCA Biopsy Positive Patients Recruited into a Large Multicentre Study of Temporal Artery Ultrasound vs Biopsy in the Diagnosis of Giant Cell Arteritis (TABUL). Nephron. 2015;129 Suppl 2:84–5.
12.
go back to reference Font RL, Prabhakaran VC. Histological parameters helpful in recognising steroid-treated temporal arteritis: an analysis of 35 cases. Br J Ophthalmol. 2007;91(2):204–9.CrossRefPubMed Font RL, Prabhakaran VC. Histological parameters helpful in recognising steroid-treated temporal arteritis: an analysis of 35 cases. Br J Ophthalmol. 2007;91(2):204–9.CrossRefPubMed
13.
go back to reference Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M, et al. The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev. 2001;10(6):489–99.CrossRefPubMed Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M, et al. The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev. 2001;10(6):489–99.CrossRefPubMed
14.
go back to reference Berglund G, Eriksson KF, Israelsson B, Kjellstrom T, Lindgarde F, Mattiasson I, et al. Cardiovascular risk groups and mortality in an urban swedish male population: the Malmo Preventive Project. J Intern Med. 1996;239(6):489–97.CrossRefPubMed Berglund G, Eriksson KF, Israelsson B, Kjellstrom T, Lindgarde F, Mattiasson I, et al. Cardiovascular risk groups and mortality in an urban swedish male population: the Malmo Preventive Project. J Intern Med. 1996;239(6):489–97.CrossRefPubMed
15.
go back to reference Jakobsson K, Jacobsson L, Warrington K, Matteson EL, Liang K, Melander O, et al. Body mass index and the risk of giant cell arteritis: results from a prospective study. Rheumatology (Oxford). 2015;54(3):433–40.CrossRef Jakobsson K, Jacobsson L, Warrington K, Matteson EL, Liang K, Melander O, et al. Body mass index and the risk of giant cell arteritis: results from a prospective study. Rheumatology (Oxford). 2015;54(3):433–40.CrossRef
16.
go back to reference Jakobsson K, Jacobsson L, Warrington K, Matteson EL, Turesson C. Biopsy findings in giant cell arteritis: relationship to baseline factors and corticosteroid treatment. Scand J Rheumatol. 2013;42(4):331–2.CrossRefPubMed Jakobsson K, Jacobsson L, Warrington K, Matteson EL, Turesson C. Biopsy findings in giant cell arteritis: relationship to baseline factors and corticosteroid treatment. Scand J Rheumatol. 2013;42(4):331–2.CrossRefPubMed
17.
go back to reference Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–8.CrossRefPubMed Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–8.CrossRefPubMed
18.
go back to reference Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Hajeer AH, Branas F, Dababneh A, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79(5):283–92.CrossRef Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Hajeer AH, Branas F, Dababneh A, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79(5):283–92.CrossRef
19.
go back to reference Salvarani C, Cimino L, Macchioni P, Consonni D, Cantini F, Bajocchi G, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 2005;53(2):293–7.CrossRefPubMed Salvarani C, Cimino L, Macchioni P, Consonni D, Cantini F, Bajocchi G, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 2005;53(2):293–7.CrossRefPubMed
20.
Metadata
Title
The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis
Authors
Karin Jakobsson
Lennart Jacobsson
Aladdin J. Mohammad
Jan-Åke Nilsson
Kenneth Warrington
Eric L. Matteson
Carl Turesson
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2016
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-016-1225-2

Other articles of this Issue 1/2016

BMC Musculoskeletal Disorders 1/2016 Go to the issue